Toray Industries has entered into a licensing-agreement collaboration with Bonac on nucleic-acid candidate BNC-1021. Under the agreement, Toray gains exclusive rights in Japan to develop, market, and manufacture (not including the bulk drug substance) idiopathic pulmonary-fibrosis candidate BNC-1021.